Developer docs
API playgroundTry for free, no card

Search company profiles

Neumora Therapeutics

Full company profile

uuid0000px7

Namestring
Neumora Therapeutics
Legal namestring
Neumora Therapeutics, Inc.
Websiteurl
neumoratx.com
Company typeenum
Public
Founded yearint
2020
Descriptiontext

Neumora Therapeutics, Inc. is a publicly traded (NASDAQ: NMRA) clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts, with a secondary office in South San Francisco. Founded in 2019–2020, the company develops precision medicines for brain diseases across neuropsychiatric, neurodegenerative, and cardiometabolic indications, supported by its Precision Toolbox — an integrated suite of translational, clinical, and computational tools designed to enable patient stratification and target identification in central nervous system drug development. The company has raised approximately $650 million in cumulative capital since inception through private rounds and a 2023 IPO.

Neumora's pipeline comprises seven clinical and preclinical programs targeting novel mechanisms of action, including NMRA-511 (V1aR antagonist for Alzheimer's agitation), NMRA-898 (M4 muscarinic receptor positive allosteric modulator for schizophrenia), NMRA-215 (brain-penetrant NLRP3 inhibitor for obesity and cardiometabolic disease), NMRA-GCASE (for Parkinson's disease), and NMRA-CK1δ (for ALS and Parkinson's disease). The company's lead program, navacaprant — a selective kappa opioid receptor antagonist for major depressive disorder — failed to meet primary or key secondary endpoints in the Phase 3 KOASTAL-2 and KOASTAL-3 studies and was discontinued in June 2026.

The business model is pre-commercial: Neumora generates no product revenue and instead funds operations through capital markets, strategic investments (notably a $100 million Amgen investment in 2021), and disease-specific grants (including a ~$2.6 million Parkinson's UK grant in 2024). Future revenue is expected to flow through traditional pharmaceutical commercialization channels — specialty pharmacies, hospital buying groups, and direct-to-prescriber models — contingent on regulatory approval of pipeline candidates. As of FY2025 the company reported a net loss of approximately $236.9 million, with $182.5 million in cash and equivalents at year-end (declining to $147.1 million in Q1 2026) and a stated runway into Q3 2027 following a June 2026 workforce reduction of approximately 35%.

Short descriptiontext

Neumora Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for brain diseases, including neuropsychiatric, neurodegenerative, and cardiometabolic disorders, supported by its Precision Toolbox platform; it is pre-revenue and trades on NASDAQ under NMRA.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersWatertown, United States
HQ citystring
Watertown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neuroscience drug development, clinical-stage biopharmaceutical, brain disease therapeutics, CNS precision medicine, neuropsychiatric disorder treatments
Industry2 codes
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Neuroscience Pharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Pre-revenue clinical-stage biotech company. Expected to generate revenue through commercialization of pipeline candidates upon regulatory approval. Primary focus is developing and commercializing novel therapies for neuropsychiatric and neurodegenerative disorders.

Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Neumora Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for brain diseases, with a pipeline of seven programs targeting novel mechanisms of action in major depressive disorder, Alzheimer's disease agitation, schizophrenia, Parkinson's disease, ALS, and obesity/cardiometabolic disease. The company combines small-molecule drug candidates with its proprietary Precision Toolbox, which integrates translational, clinical, and computational tools to identify and serve patient populations most likely to respond to therapy.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Navacaprant showed 15.7-point reduction on CMAI scale in Phase 1b for Alzheimer's agitation
+2 more records
Product overview1 text field

Neumora Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of precision medicines for brain diseases. The company's therapeutic pipeline consists of seven programs targeting novel mechanisms of action for neuropsychiatric disorders and neurodegenerative diseases. Lead program navacaprant is a kappa opioid receptor antagonist for major depressive disorder in Phase 3. Other programs include NMRA-511 (V1aR antagonist for Alzheimer's agitation), NMRA-898 (M4 modulator for schizophrenia), NMRA-215 (NLRP3 inhibitor for obesity), NMRA-GCASE (for Parkinson's), and NMRA-CK1δ (for ALS/Parkinson's). The pipeline is supported by the company's Precision Toolbox, which integrates translational, clinical, and computational tools to enable precision medicine approaches.

Product and service6 records
1Navacaprant (NMRA-001)
CategoryInvestigational CNS pharmaceutical - Neuropsychiatric
Description

A highly selective, novel kappa opioid receptor (KOR) antagonist that was in Phase 3 development as a potential once-daily oral monotherapy for major depressive disorder, designed to modulate dopamine and reward processing pathways via a non-serotonergic mechanism. Development was discontinued after Phase 3 studies failed to achieve statistical significance on primary or key secondary endpoints.

2NMRA-511
CategoryInvestigational CNS pharmaceutical - Neurodegenerative
Description

A vasopressin 1a receptor (V1aR) antagonist in development for the treatment of agitation in Alzheimer's Disease, with projected peak U.S. sales of $1.8 billion. Phase 1b data showed a 15.7-point reduction on the CMAI scale, with effect sizes of 0.51-0.64 in a pre-specified elevated-anxiety subpopulation.

3NMRA-898
CategoryInvestigational CNS pharmaceutical - Neuropsychiatric
Description

An M4 muscarinic receptor positive allosteric modulator (PAM) in development for the treatment of schizophrenia, targeting a novel muscarinic receptor mechanism distinct from current antipsychotics.

4NMRA-215
CategoryInvestigational pharmaceutical - Cardiometabolic
Description

A brain-penetrant, oral NLRP3 inhibitor in development for obesity, with potential for treatment of cardiometabolic disease, being evaluated both as monotherapy and in combination with existing GLP-1 therapies such as semaglutide.

5NMRA-GCASE
CategoryInvestigational CNS pharmaceutical - Neurodegenerative
Description

A glucocerebrosidase (GCASE) activator in development for Parkinson's Disease, designed to increase glucocerebrosidase activity as a potential disease-modifying therapy.

6NMRA-CK1δ
CategoryInvestigational CNS pharmaceutical - Neurodegenerative
Description

A CK1δ inhibitor in development for amyotrophic lateral sclerosis (ALS) and Parkinson's Disease, targeting casein kinase 1 delta to address neurodegenerative disease pathology.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles18 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors19 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Neumora Therapeutics

Neuroscience Pharmaceuticalsneumoratx.com

Neumora Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for brain diseases, including neuropsychiatric, neurodegenerative, and cardiometabolic disorders, supported by its Precision Toolbox platform; it is pre-revenue and trades on NASDAQ under NMRA.

What Neumora Therapeutics does

Neumora Therapeutics, Inc. is a publicly traded (NASDAQ: NMRA) clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts, with a secondary office in South San Francisco. Founded in 2019–2020, the company develops precision medicines for brain diseases across neuropsychiatric, neurodegenerative, and cardiometabolic indications, supported by its Precision Toolbox — an integrated suite of translational, clinical, and computational tools designed to enable patient stratification and target identification in central nervous system drug development. The company has raised approximately $650 million in cumulative capital since inception through private rounds and a 2023 IPO.

Neumora's pipeline comprises seven clinical and preclinical programs targeting novel mechanisms of action, including NMRA-511 (V1aR antagonist for Alzheimer's agitation), NMRA-898 (M4 muscarinic receptor positive allosteric modulator for schizophrenia), NMRA-215 (brain-penetrant NLRP3 inhibitor for obesity and cardiometabolic disease), NMRA-GCASE (for Parkinson's disease), and NMRA-CK1δ (for ALS and Parkinson's disease). The company's lead program, navacaprant — a selective kappa opioid receptor antagonist for major depressive disorder — failed to meet primary or key secondary endpoints in the Phase 3 KOASTAL-2 and KOASTAL-3 studies and was discontinued in June 2026.

The business model is pre-commercial: Neumora generates no product revenue and instead funds operations through capital markets, strategic investments (notably a $100 million Amgen investment in 2021), and disease-specific grants (including a ~$2.6 million Parkinson's UK grant in 2024). Future revenue is expected to flow through traditional pharmaceutical commercialization channels — specialty pharmacies, hospital buying groups, and direct-to-prescriber models — contingent on regulatory approval of pipeline candidates. As of FY2025 the company reported a net loss of approximately $236.9 million, with $182.5 million in cash and equivalents at year-end (declining to $147.1 million in Q1 2026) and a stated runway into Q3 2027 following a June 2026 workforce reduction of approximately 35%.

Neumora Therapeutics firmographics

Firmographics
Name
Neumora Therapeutics
Legal name
Neumora Therapeutics, Inc.
Website
https://neumoratx.com
Company type
Public
Founded year
2020
Operating status
Operating
Headcount range
51–100 employees
Short description
Neumora Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for brain diseases, including neuropsychiatric, neurodegenerative, and cardiometabolic disorders, supported by its Precision Toolbox platform; it is pre-revenue and trades on NASDAQ under NMRA.
Ownership category
akta.pro rank

Neumora Therapeutics industry classification

Industry
Product category
Neuroscience Pharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals

Keywords

  • Neuroscience drug development
  • Clinical-stage biopharmaceutical
  • Brain disease therapeutics
  • CNS precision medicine
  • Neuropsychiatric disorder treatments

Where Neumora Therapeutics is headquartered

Location

Headquarters

HQ city
Watertown
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Neumora Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: Pre-revenue clinical-stage biotech company. Expected to generate revenue through commercialization of pipeline candidates upon regulatory approval. Primary focus is developing and commercializing novel therapies for neuropsychiatric and neurodegenerative disorders.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Neumora Therapeutics product offering

Product offering

Core offering

Neumora Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for brain diseases, with a pipeline of seven programs targeting novel mechanisms of action in major depressive disorder, Alzheimer's disease agitation, schizophrenia, Parkinson's disease, ALS, and obesity/cardiometabolic disease. The company combines small-molecule drug candidates with its proprietary Precision Toolbox, which integrates translational, clinical, and computational tools to identify and serve patient populations most likely to respond to therapy.

Product overview

Neumora Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of precision medicines for brain diseases. The company's therapeutic pipeline consists of seven programs targeting novel mechanisms of action for neuropsychiatric disorders and neurodegenerative diseases. Lead program navacaprant is a kappa opioid receptor antagonist for major depressive disorder in Phase 3. Other programs include NMRA-511 (V1aR antagonist for Alzheimer's agitation), NMRA-898 (M4 modulator for schizophrenia), NMRA-215 (NLRP3 inhibitor for obesity), NMRA-GCASE (for Parkinson's), and NMRA-CK1δ (for ALS/Parkinson's). The pipeline is supported by the company's Precision Toolbox, which integrates translational, clinical, and computational tools to enable precision medicine approaches.

Differentiator

Problem solved

Functional benefit

Products and services

  • Navacaprant (NMRA-001) A highly selective, novel kappa opioid receptor (KOR) antagonist that was in Phase 3 development as a potential once-daily oral monotherapy for major depressive disorder, designed to modulate dopamine and reward processing pathways via a non-serotonergic mechanism. Development was discontinued after Phase 3 studies failed to achieve statistical significance on primary or key secondary endpoints.
  • NMRA-511 A vasopressin 1a receptor (V1aR) antagonist in development for the treatment of agitation in Alzheimer's Disease, with projected peak U.S. sales of $1.8 billion. Phase 1b data showed a 15.7-point reduction on the CMAI scale, with effect sizes of 0.51-0.64 in a pre-specified elevated-anxiety subpopulation.
  • NMRA-898 An M4 muscarinic receptor positive allosteric modulator (PAM) in development for the treatment of schizophrenia, targeting a novel muscarinic receptor mechanism distinct from current antipsychotics.
  • NMRA-215 A brain-penetrant, oral NLRP3 inhibitor in development for obesity, with potential for treatment of cardiometabolic disease, being evaluated both as monotherapy and in combination with existing GLP-1 therapies such as semaglutide.
  • NMRA-GCASE A glucocerebrosidase (GCASE) activator in development for Parkinson's Disease, designed to increase glucocerebrosidase activity as a potential disease-modifying therapy.
  • NMRA-CK1δ A CK1δ inhibitor in development for amyotrophic lateral sclerosis (ALS) and Parkinson's Disease, targeting casein kinase 1 delta to address neurodegenerative disease pathology.

Quantifiable outcome

  • Navacaprant showed 15.7-point reduction on CMAI scale in Phase 1b for Alzheimer's agitation
  • +2 more outcomes

Companies that use Neumora Therapeutics

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Neumora Therapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Neumora Therapeutics partnerships and signals

Strategic signal

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Neumora Therapeutics competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Neumora Therapeutics social profiles

Digital presence

Neumora Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Neumora Therapeutics leadership team

Management profile

Number of profiles

Profiles18 records

Neumora Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Neumora Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neumora Therapeutics

What does Neumora Therapeutics do?

Neumora Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for brain diseases, with a pipeline of seven programs targeting novel mechanisms of action in major depressive disorder, Alzheimer's disease agitation, schizophrenia, Parkinson's disease, ALS, and obesity/cardiometabolic disease. The company combines small-molecule drug candidates with its proprietary Precision Toolbox, which integrates translational, clinical, and computational tools to identify and serve patient populations most likely to respond to therapy.

Is Neumora Therapeutics a public or private company?

Neumora Therapeutics is a public company. It is classified as public and is currently operating.

When was Neumora Therapeutics founded?

Neumora Therapeutics was founded in 2020. It employs 51 to 100 people.

Where is Neumora Therapeutics based?

Neumora Therapeutics is headquartered in Watertown, United States, in the North America region.

How does Neumora Therapeutics make money?

One revenue line is on record: pharmaceutical Product Sales.

Does Neumora Therapeutics have an API?

No public API is recorded for Neumora Therapeutics.

What industry is Neumora Therapeutics in?

Neumora Therapeutics's product category is Neuroscience Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Quiver QuantitativeNeumora Reports $34.4 Million Third-Quarter Loss, Submits NMRA-215 IND | NMRA Stock NewsNeumora Therapeutics reported a Q3 2026 net loss of $34.4 million, down from $56.8 million a year earlier, with cash of $85.7 million. The company submitted an IND for NMRA-215, an oral NLRP3 inhibitor for obesity and cardiometabolic disease, and reported expansion cohort results for NMRA-511.American Banking and Market NewsNeumora Therapeutics, Inc. (NASDAQ:NMRA) Stock Has Consensus Target Price of $6.57Neumora Therapeutics shares have an average analyst target price of $6.57 with a consensus of Moderate Buy. Insider Daljit Singh Aurora sold 21,055 shares at $1.60, and the stock opened at $0.43. The company reported Q2 EPS of -$0.23, beating estimates.MarketBeatNeumora Therapeutics (NMRA) Projected to Release Quarterly Earnings on ThursdayNeumora Therapeutics is expected to report Q3 2026 earnings on Thursday, November 5th, with analysts projecting a loss of $0.19 per share. The company previously beat estimates with a $0.23 loss, and analysts average a $0.83 loss for the current fiscal year. The stock opened at $0.39, and the consensus target price is $6.57.American Banking and Market NewsNeumora Therapeutics, Inc. (NASDAQ:NMRA) Stock Has Consensus Target Price of $6.57 According to BrokeragesNeumora Therapeutics shares have a consensus "Moderate Buy" rating with a $6.57 price target. The company reported Q2 EPS of -$0.23, beating estimates, and insiders sold 453,833 shares in the last 90 days. Analysts expect a fiscal-year EPS of -$0.83.MarketBeatNeumora Therapeutics, Inc. (NMRA) - What Are Researchers Thinking About This Stock?Neumora Therapeutics received a Moderate Buy consensus from nine analysts, with an average price target of $6.57. The stock opened at $0.37, down 15.3%, and insiders sold 453,833 shares in the last 90 days. The company reported Q2 EPS of -$0.23, beating estimates, and analysts expect -$0.83 EPS for the year.MarketBeatNeumora Therapeutics (NASDAQ:NMRA) Cut to Strong Sell at Wall Street ZenWall Street Zen downgraded Neumora Therapeutics to a strong sell rating on Saturday. The company's stock opened at $0.48, and analysts have a consensus Moderate Buy rating with a $6.57 target price. Neumora reported a loss of $0.23 per share for the quarter, beating estimates.AInvestOne Buzz, Three TellsThree biotechs showed unusual options volume, but put/call splits reveal opposite directional bets: Neumora's puts, United Therapeutics' even split, and Edgewise's calls. The spike is inflated by quarterly options expiration, and the volume multiple tells nothing about direction.AInvestThe $117 Million Countdown: What Neumora Therapeutics Left Behind After Three FailuresNeumora Therapeutics reported $116.8 million in cash as of June 30, 2026, down from $182.5 million, after three Phase 3 failures of its depression drug navacaprant, a 35% workforce cut and a new CEO. The company burned $236.9 million in 2025 and $43.1 million in Q2 2026, with $80.7 million in debt and $44.5 million in equity. Management says cash provides runway into Q3 2027.Investing.comNeumora Therapeutics COO Aurora disposes of $269,966 in stock By Investing.comDaljit Singh Aurora, COO of Neumora Therapeutics, sold approximately $269,966 worth of shares in August 2026 following the exercise of stock options. This transaction occurred amidst significant strategic shifts for Neumora, including the discontinuation of its navacaprant development program after failed Phase 3 trials and a 35% workforce reduction.Markets DailyDaljit Singh Aurora Sells 21,055 Shares of Neumora Therapeutics (NASDAQ:NMRA) StockInsider Daljit Singh Aurora sold a significant portion of his shares in Neumora Therapeutics, reducing his position by over 30% through multiple transactions between August 17 and August 21. The sales occurred at average prices ranging from $1.50 to $1.65 per share, bringing the total value of the disclosed transactions to over $500,000. This divestment follows recent quarterly earnings where the company reported a loss but beat analyst estimates.